Fennec Pharmaceuticals Inc. filings document formal disclosures for its commercial specialty pharmaceutical business, PEDMARK® product updates, and Nasdaq-listed common shares. Recent Form 8-K reports cover financial results, scientific presentations and investigator-sponsored studies involving sodium thiosulfate injection, and a license agreement resolving litigation tied to a proposed generic version of PEDMARK.
The company’s proxy materials cover director elections, board composition, executive compensation, equity awards, and shareholder voting matters. Other current reports disclose governance changes, registered common shares with no par value, and exhibits furnished with press releases concerning business, clinical, and product-related developments.
FENNEC PHARMACEUTICALS INC. director Chris A. Rallis received a compensation-related stock option grant. On June 10, 2026, he was granted a non-qualified option to purchase 20,000 common shares at an exercise price of $8.70 per share under the company’s Equity Incentive Plan.
The option is 100% vested on the grant date and expires on June 10, 2036. Following this award, Rallis holds stock options for a total of 200,000 shares, according to the filing. This is an equity grant, not an open-market share purchase.
Fennec Pharmaceuticals Inc. held its annual shareholder meeting, where investors approved all proposals and director nominees. Five directors were elected, with each receiving over 20 million votes for and similar broker non-vote levels.
Shareholders approved appointing Haskell & White LLP as independent public accounting firm, an advisory vote on executive compensation, and set advisory votes on pay to occur every year. They also approved amendments to the 2020 Equity Incentive Plan and ratified and approved a new 2026 Equity Inducement Plan, with officer and director holdings deducted from the "for" tally on the 2020 plan amendment vote.
FENNEC PHARMACEUTICALS INC. director Rosty Raykov reported a series of routine equity compensation transactions. He received 2,778 common shares at no cost from the release of previously awarded restricted shares, then exercised 15,597 stock options at $2.45 per share.
To cover tax obligations tied to the option exercise, 9,747 common shares were sold at $9.62 per share pursuant to a Rule 10b5-1 trading plan adopted on September 19, 2025. Following these transactions, Raykov directly holds 130,079 common shares and 1,556,195 stock options.
Rostislav Raykov reports a proposed sale of 9,747 shares of Common Stock via a stock option exercise dated 06/01/2026. The filing lists prior open-market dispositions in the three months ended May 2026: 10,079 shares on 03/02/2026, 10,946 shares on 04/01/2026, and 10,781 shares on 05/01/2026, with the corresponding proceeds shown in the excerpt. The sale method is noted as cash.
FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a small share award under the company’s equity compensation. On May 31, 2026, she acquired 156 common shares at $0.00 per share, representing shares released from restriction from an award granted on March 28, 2025. Following this vesting-related acquisition, she directly holds 24,176 common shares, indicating a routine, compensation-driven increase in her ownership rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Commercial Officer Terry L. Evans reported a compensation-related stock event. On May 31, 2026, Evans acquired 168 Common Shares at a stated price of $0.00 per share, characterized as a grant, award, or similar acquisition.
According to the filing, these shares represent a release from restriction on shares originally awarded on March 28, 2025. Following this transaction, Evans directly holds a total of 21,015 Common Shares of Fennec Pharmaceuticals, reflecting a routine increase in his equity-based compensation holdings rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. Chief Medical Officer Sayad Pierre Sargis acquired 168 Common Shares through a grant classified as a “grant, award, or other acquisition.” The shares were released from restriction on equity originally awarded on 3/28/2025 and carried no purchase price.
Following this compensation-related acquisition, Sargis directly holds 21,015 Common Shares. The event reflects routine equity compensation rather than an open‑market share purchase or sale.
Fennec Pharmaceuticals Inc. reported that Chief Executive Officer Jeffrey S. Hackman acquired 1,159 Common Shares as a grant or award. The shares were released from restriction from an award originally granted on 3/28/2025 and carried a transaction price of $0.00 per share.
Following this compensation-related acquisition, Hackman directly owns 62,825 Common Shares. The filing reflects routine equity compensation rather than an open-market purchase or sale.
FENNEC PHARMACEUTICALS INC. reported that Chief Financial Officer Robert Andrade acquired 1,703 common shares as a grant or award on May 31, 2026. The shares were released from restrictions tied to prior awards dated May 16, 2024 and March 28, 2025, and carried no purchase price. After this vesting event, Andrade directly holds 289,269 common shares.
Fennec Pharmaceuticals Inc. reported that new research on PEDMARK® (sodium thiosulfate injection) will be presented at the 2026 American Society of Clinical Oncology Annual Meeting. Four independently led studies examine use of PEDMARK across pediatric, adolescent, young adult and adult patients receiving cisplatin-based chemotherapy.
Key data include a Japanese Phase 2/3 trial in 27 pediatric and adolescent patients where hearing loss rates of 16–24% with PEDMARK were lower than historically reported 56–63% with cisplatin alone, and real‑world series in young adults and adults with head and neck cancer suggesting feasible integration of PEDMARK several hours after cisplatin without compromising antitumor activity and with preservation of clinically significant hearing. The company also reiterates that PEDMARK is the first FDA‑approved therapy to reduce cisplatin‑related ototoxicity in pediatric patients with localized, non‑metastatic solid tumors.